缬沙坦治疗糖尿病肾病疗效观察  

The Effect of Valsartan on Diabetic Nephropathy

作　　者：冯尤健[1] 张莹[1] 陈祥彪[1] 刘桑燕[1] 巫晓强[1] 李肇暖[1] 

机构地区：[1]福建省三明市第二医院,福建永安366000

出　　处：《蛇志》2004年第1期24-26,共3页Journal of Snake

摘　　要：目的　观察血管紧张素 1型受体拮抗剂 ( AT1Ra)缬沙坦 ( Valsartan)对伴大量白蛋白尿的临床糖尿病肾病的治疗作用。　方法　　 32例 2型糖尿病患者 ,2 4 h尿白蛋白排泄率 ( 2 4 h UA ER) >2 0 0μg/min,均伴高血压 ,维持原糖尿病治疗不变 ,分组比较应用缬沙坦 ( 80 mg/ d)或贝那普利 ( 10 mg/ d)治疗 8周前后平均动脉压 ( MAP)、 2 4 h U AER、 Hb A1c、尿酸 ( UA)等指标的变化。　结果　缬沙坦治疗组和贝那普利治疗组 2 4 h U AER分别由 ( 70 3.2± 987.9) μg/ min降至 ( 6 6 4.2± 970 .6 ) μg/ min ( P<0 .0 1)和由 ( 778.6± 10 0 5.0 ) μg/ min降至 ( 734 .9± 996 .0 ) μg/ m in( P <0 .0 1)。二者疗效相似 ,且均与血压变化不相关。　结论　AT1Ra缬沙坦可以降低临床糖尿病肾病的尿蛋白 ,其肾脏保护作用除了与降血压有关 。Objectve To observe the effect of angiotens in Ⅱ1type receptor antagonists(ATIRa) Valsartan on the clinical diabetic nephropa thy with macroalbuminuria Methods 32 cases of type 2 diabetes mellitus(DM) with hypertension 24h ur ine albumine excretion rate(24hUAER) >200μg/min were selected The changes of mean arterial pressure(MAP),24h UAER,HbA 1 c,uratic acid(UA) were compared b efore and after administration of valsartan(80mg/d) or Benazepril(10mg/d) for 8 weeks without changing the previous management of DM Results 24h UAER decreased from (703 2±987 9)to (664 2±970 6)μg /mi n(P<0 01)in valsartan group and from(778 6±1005 0)to (734 9±996 0)μ g/min(P<0 01) in Benazepril group These therapeutic effects were similar and n ot related to the change of blood pressure Conclusons ATL Ra valsartan can reduce the alduminuria of clinical diabe tic nephropathy The effect of renoprotection is not solely dependent on the low ering blood pressure levels,other mechanism may be involved

关 键 词：糖尿病肾病 DN 缬沙坦 尿蛋白 治疗效果 高血压 血管紧张素Ⅱ1型受体拮抗剂 AT1RA 

分 类 号：R587.1[医药卫生—内分泌] R972.4[医药卫生—内科学]